Allogene Therapeutics
ALLO
86 hedge funds and large institutions have $1.88B invested in Allogene Therapeutics in 2019 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 30 increasing their positions, 19 reducing their positions, and 12 closing their positions.
58% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 12
58% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 19
12% more capital invested
Capital invested by funds: $1.68B → $1.88B (+$207M)
9% more funds holding
Funds holding: 79 → 86 (+7)
2.25% more ownership
Funds ownership: 51.6% → 53.85% (+2.3%)
21% less call options, than puts
Call options by funds: $2.45M | Put options by funds: $3.11M
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$37.4M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$24.5M |
| 3 |
State Street
Boston,
Massachusetts
|
+$22.4M |
| 4 |
BII
Bainco International Investors
Boston,
Massachusetts
|
+$10.3M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$8.53M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
-$19.2M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$16.6M |
| 3 |
DP
DSAM Partners
London,
United Kingdom
|
-$4.62M |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$4.12M |
| 5 |
SC
Samlyn Capital
New York
|
-$4.04M |
ALLO Hedge Fund Activity: Q1 2019 in Review
86 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Allogene Therapeutics (ALLO) for Q1 2019, worth a combined $1.88B — up 12% from $1.68B a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new ALLO positions and 12 closed out — a net gain of 7 holders — while 30 added to existing stakes and 19 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $37.4M. The largest seller was Waddell & Reed Financial, cutting an estimated $19.2M.
- 86 institutional investors held Allogene Therapeutics (ALLO) as of Q1 2019, up from 79 in Q4 2018.
- Funds reported $1.88B of Allogene Therapeutics stock for Q1 2019, up 12% quarter-over-quarter.
- 19 funds opened new Allogene Therapeutics positions in Q1 2019 and 12 closed out, a net change of +7 holders.
- The largest Allogene Therapeutics buyer in Q1 2019 was Fidelity Investments, an estimated $37.4M added.
- The largest Allogene Therapeutics seller in Q1 2019 was Waddell & Reed Financial, an estimated $19.2M sold.
Based on aggregated 13F filings for Q1 2019.